Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

• Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed

  Business - CNBC - October 30

• Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall

  Business - CNBC - October 31
• 

  Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

  Business - Financial Times - October 30

• Airbnb is seeing ‘strong demand trends’ — with these caveats

  Business - MarketWatch - November 8

More from MarketWatch

• Existing-home sales rise in October but remain at a low level

  Business - MarketWatch - 8 minutes ago

• The actor Danny McBride’s best financial advice? Never buy a boat.

  Business - MarketWatch - 9 minutes ago

• BJ’s stock rises on first membership-fee increase in 7 years

  Business - MarketWatch - 20 minutes ago

• Beyond Inc. was set to rescue the Container Store. Now that’s off the table.

  Business - MarketWatch - 21 minutes ago

• The last time inflation was projected to get worse, this investment was popular. Why it’s ‘unloved’ now.

  Business - MarketWatch - 24 minutes ago